• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Galapagos Receives Transparency Notifications from Bank of America

    3/4/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLPG alert in real time by email

    Mechelen, Belgium; March 4, 2026, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received transparency notifications from Bank of America.

    Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications on February 27 and March 2, 2026, from Bank of America Corporation. The initial notification indicates that Bank of America Corporation, as controlling entity, and its controlled entity, BofA Securities, Inc., individually crossed above the threshold of 5% of Galapagos' voting rights on February 26, 2026, including exceeding the threshold of 5% for equivalent financial instruments, as a result of an acquisition of Galapagos' equivalent financial instruments. Subsequently on March 2, Galapagos received a notification indicating that BofA Securities, Inc. fell below the 5% threshold of Galapagos' voting rights again on February 27, 2026 following the disposal of such instruments.

    On March 2, 2026, Bank of America Corporation (taking into account the holding of its affiliates) owned 292,642 voting rights and 3,491,679 equivalent financial instruments, representing together 5.74% of Galapagos' currently outstanding 65,897,071 shares.

    Summary of the transactions:

    Date on which the threshold was crossedDate of notificationDirect voting rights after the transactionEquivalent financial instruments after the transactionTotal (%)

    voting rights
    February 26, 2026February 27, 20260.20%5.49%5.69%
    February 27, 2026March 2, 20260.44%5.30%5.74%

    Content of the notifications from Bank of America Corporation:

    The notification dated March 2, 2026, contains the following information:

    • Date of notification: March 2, 2026
    • Date on which the threshold is crossed: February 27, 2026
    • Threshold of voting rights crossed (in %): 5%
    • Notification by: Bank of America Corporation
    • Denominator: 65,897,071
    • Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting securities
    • Notified details:



    A) Voting RightsPrevious notificationAfter the transaction
     # of voting rights# of voting rights% of voting rights
    Holder of voting rights Linked to securitiesNot linked to securitiesLinked to securitiesNot linked to securities
    Bank of America Corporation00 0.00% 
    Bank of America, National Association12,44012,440 0.02% 
    Merrill Lynch International103,93495,048 0.14% 
    Managed Account Advisors LLC33 0.00% 
    BofA Securities, Inc.0170,568 0.02% 
    Merrill Lynch, Pierce, Fenner & Smith

    Incorporated
    14,46214,462 0.00% 
    U.S. Trust Company of Delaware121121 0.26% 
    Subtotal130,960292,642 0.44% 
     TOTAL292,64200.44%0.00%



    B) Equivalent financial instrumentsAfter the transaction
    Holder of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
    Merrill Lynch InternationalRight to Recall  141,6840.22%physical
    Merrill Lynch InternationalRights of Use  1000.00%physical
    BofA Securities, Inc.Right to Recall  24,7000.04%physical
    BofA Securities, Inc.Rights of Use  3,163,2904.80%physical
    Merrill Lynch InternationalPhysical Call Option19/06/2026 100,0000.15%physical
    Bank of America, National AssociationSwaps15/10/2027 360.00%cash
    Bank of America, National AssociationSwaps31/01/2028 7820.00%cash
    Bank of America, National AssociationSwaps15/04/2027 14,6790.02%cash
    Bank of America, National AssociationSwaps29/02/2028 7410.00%cash
    Merrill Lynch InternationalSwaps15/01/2027 9,1670.01%cash
    Merrill Lynch InternationalSwaps30/04/2026 14,3500.02%cash
    Merrill Lynch InternationalSwaps02/07/2026 1,1130.00%cash
    Merrill Lynch InternationalSwaps01/11/2027 5,7260.01%cash
    Merrill Lynch InternationalSwaps15/04/2027 14,6790.02%cash
    Merrill Lynch InternationalSwaps15/10/2027 360.00%cash
    Merrill Lynch InternationalSwaps31/03/2027 5960.00%cash
     TOTAL  3,491,6795.30% 



    TOTAL (A&B)# of voting rights% of voting rights
     3,784,3215.74%

    The chain of control has been described at the end of the notification (section 11) and can be found here.

    Content of the notifications from Bank of America Corporation:

    The notification dated February 27, 2026, contains the following information:

    • Date of notification: February 27, 2026
    • Date on which the threshold is crossed: February 26, 2026
    • Threshold of voting rights crossed (in %): 5%
    • Notification by: Bank of America Corporation
    • Denominator: 65,897,071
    • Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting securities
    • Notified details:



    A) Voting RightsPrevious notificationAfter the transaction
     # of voting rights# of voting rights% of voting rights
    Holder of voting rights Linked to securitiesNot linked to securitiesLinked to securitiesNot linked to securities
    Bank of America Corporation00 0.00% 
    Bank of America, National Association12,48112,440 0.02% 
    Merrill Lynch International77,455103,934 0.16% 
    Managed Account Advisors LLC33 0.00% 
    BofA Securities, Inc.00 0.00% 
    Merrill Lynch, Pierce, Fenner & Smith

    Incorporated
    14,46214,462 0.02% 
    U.S. Trust Company of Delaware121121 0.00% 
    Subtotal104,522130,960 0.20% 
     TOTAL130,96000.20%0.00%



    B) Equivalent financial instrumentsAfter the transaction
    Holder of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
    Merrill Lynch InternationalRight to Recall  141,6840.22%physical
    BofA Securities, Inc.Right to Recall  24,7000.04%physical
    BofA Securities, Inc.Rights of Use  3,289,3404.99%physical
    Merrill Lynch InternationalPhysical Call Option19/06/2026 100,0000.15%physical
    Bank of America, National AssociationSwaps31/01/2028 7820.00%cash
    Bank of America, National AssociationSwaps15/04/2027 14,6790.02%cash
    Bank of America, National AssociationSwaps29/02/2028 7360.00%cash
    Merrill Lynch InternationalSwaps15/01/2027 9,1670.01%cash
    Merrill Lynch InternationalSwaps30/04/2026 14,3100.02%cash
    Merrill Lynch InternationalSwaps02/07/2026 1,1060.00%cash
    Merrill Lynch InternationalSwaps01/11/2027 5,7260.01%cash
    Merrill Lynch InternationalSwaps27/02/2026 5940.00%cash
    Merrill Lynch InternationalSwaps15/04/2027 14,6790.02%cash
    Merrill Lynch InternationalSwaps30/06/2026 120.00%cash
     TOTAL  3,617,5155.49% 



    TOTAL (A&B)# of voting rights% of voting rights
     3,748,4755.69%

    The chain of control has been described at the end of the notification (section 11) and can be found here.

    About Galapagos

    Galapagos is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Galapagos prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit www.glpg.com or follow us on LinkedIn or X.

    For further information, contact Galapagos:

    Investor Relations

    Glenn Schulman

    +1 412 522 6239

    [email protected]

    Media

    Media

    Katie Morris

    +1 952 288 6821

    [email protected]

    Visit us at www.glpg.com or follow us on LinkedIn or X.


    1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.

    Attachment

    • Galapagos Receives Transparency Notification from Bank of America.pdf


    Primary Logo

    Get the next $GLPG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLPG

    DatePrice TargetRatingAnalyst
    10/22/2025$40.00Market Perform → Outperform
    Leerink Partners
    8/5/2025Hold → Sell
    Deutsche Bank
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    11/20/2024Hold → Reduce
    Kepler
    9/9/2024$24.00Market Perform
    Leerink Partners
    8/2/2024Outperform → Mkt Perform
    Raymond James
    3/28/2024$41.00 → $31.00Neutral → Underperform
    BofA Securities
    3/7/2024$38.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $GLPG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Galapagos Receives Transparency Notifications from Bank of America

    Mechelen, Belgium; March 4, 2026, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications on February 27 and March 2, 2026, from Bank of America Corporation. The initial notification indicates that Bank of America Corporation, as controlling entity, and its controlled entity, BofA Securities, Inc., individually crossed above the threshold of 5% of Galapagos' voting rights on February 26, 2026, including exceeding the threshold of 5% for equivalent financial instruments, as a result of an acquisition of Galapagos' equivalen

    3/4/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

    Strategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business development-led growth strategy 2026 year-end cash expected to be in the range of €2.775 to €2.850 billion, with reduced cell therapy one-time restructuring cash costs of €25 million to an updated range of €125 to €175 million Management to host conference call tomorrow, February 24, 2026, at 14:00 CET / 8:00 am ET   Mechelen, Belgium; February 23, 2026, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today reported its financial results for the full yea

    2/23/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors

    Dr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board Mechelen, Belgium; February 19, 2026, 22:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced the appointment by way of co-optation of Dr. Paulo Fontoura as Non-Executive Independent Director to its Board of Directors, effective February 9, 2026. "We are pleased to welcome Paulo to our Board," said Jérôme Contamine, Chair of the Board of Galapagos. "His global leadership experience, deep understanding of clinical development strategy, and proven track record of assessing and advancing differentiated assets will strengthen the Board's ability to provide strategic guida

    2/19/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    SEC Filings

    View All

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    3/4/26 4:25:58 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    2/23/26 5:15:42 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    2/19/26 4:43:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Galapagos NV upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Galapagos NV from Market Perform to Outperform and set a new price target of $40.00

    10/22/25 7:00:32 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Deutsche Bank

    Deutsche Bank downgraded Galapagos NV from Hold to Sell

    8/5/25 3:22:16 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously

    2/14/25 8:06:36 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Leadership Updates

    Live Leadership Updates

    View All

    Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors

    Dr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board Mechelen, Belgium; February 19, 2026, 22:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced the appointment by way of co-optation of Dr. Paulo Fontoura as Non-Executive Independent Director to its Board of Directors, effective February 9, 2026. "We are pleased to welcome Paulo to our Board," said Jérôme Contamine, Chair of the Board of Galapagos. "His global leadership experience, deep understanding of clinical development strategy, and proven track record of assessing and advancing differentiated assets will strengthen the Board's ability to provide strategic guida

    2/19/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development

    New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board's composition with the Company's strategic direction and support its focus on transformational business development to build a pipeline of novel medicines in areas of high unmet medical need. Seasoned biopharma executive Dr. Neil Johnston has been appointed to the Board of Directors by way of co-

    10/30/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Announces Appointment of Fred Blakeslee as General Counsel

    Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025. Blakeslee is succeeding Ms. Valeria Cnossen, who will leave the Company after a short transition period. "We are very pleased to welcome Fred to the executive team," said Henry Gosebruch, CEO of Galapagos. "He brings a unique combination of top-tier legal expertise, global business transaction experience, and deep strategic understanding of the biopharma ecosystem. His proven track record of negotiating complex, high-impact partnerships and acquisitions, and fostering cross-f

    10/16/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Galapagos NV

    SC 13G/A - GALAPAGOS NV (0001421876) (Subject)

    11/12/24 9:55:16 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Galapagos NV

    SC 13D/A - GALAPAGOS NV (0001421876) (Subject)

    10/8/24 4:35:06 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Galapagos NV

    SC 13D - GALAPAGOS NV (0001421876) (Subject)

    8/23/24 4:01:26 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Financials

    Live finance-specific insights

    View All

    Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

    Strategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business development-led growth strategy 2026 year-end cash expected to be in the range of €2.775 to €2.850 billion, with reduced cell therapy one-time restructuring cash costs of €25 million to an updated range of €125 to €175 million Management to host conference call tomorrow, February 24, 2026, at 14:00 CET / 8:00 am ET   Mechelen, Belgium; February 23, 2026, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today reported its financial results for the full yea

    2/23/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

    Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the Company's cell therapy activities. On October 21, 2025, Galapagos announced its intention to wind down its cell therapy activities following a comprehensive strategic review and sale process, including an exploration of potential divestment options. This decision was subject to the conclusion of consultations with works councils in Belgium and the Netherlands, which have now been completed. "We have now co

    1/5/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update

    Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion   Management to host a conference call tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET Mechelen, Belgium; November 5, 2025, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced its financial results for the first nine m

    11/5/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care